Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan · Delayed Price · Currency is TWD 63.10
+7.10 (12.68%)
At close: Feb 11, 2026
Elixiron Immunotherapeutics (Cayman) Limited Company Description
Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland.
It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer.
Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is headquartered in Taipei, Taiwan.
Elixiron Immunotherapeutics (Cayman) Limited
| Country | Cayman Islands |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Hung-Kai Chen |
Contact Details
Address: No. 508, Section 7 Taipei, 115011 Taiwan | |
| Phone | 886 2 2782 7700 |
| Website | elixiron.com |
Stock Details
| Ticker Symbol | 7871 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hung-Kai Chen | Chief Executive Officer |
| James Hsu | Chief Financial Officer |